Acute Metabolic Outcomes in Diabetic Patients Hospitalized for COVID-19 (DMD-COV) (DMD-COV)
Acute Metabolic Outcomes of Diabetic Patients Hospitalized for COVID-19 in Algeria: A Prospective Cohort Study (DMD-COV)
Diabetes is a major risk factor for severe COVID-19 and poor clinical outcomes during hospitalization. However, little is known about the medium- and long-term metabolic consequences of COVID-19 in people with diabetes after hospital discharge.
The DMD-COV study is a prospective, multicenter observational cohort conducted in Algeria. Its aim is to evaluate the cardio-metabolic outcomes of adult patients with diabetes who were hospitalized for confirmed COVID-19 and survived the acute phase of the infection.
Adult patients with type 1 or type 2 diabetes will be included during hospitalization or within 30 days after hospital discharge. Participants will be followed for up to one year after discharge, with scheduled evaluations at baseline, 3 months, 6 months, and 12 months.
During follow-up, clinical, biological, and therapeutic data will be collected, including glycemic control (HbA1c), body weight, lipid profile, kidney function, and diabetes treatments. The main outcome is the proportion of patients achieving their individualized HbA1c target at 6 months and 12 months after hospitalization for COVID-19.
The results of this study will help to better understand the long-term metabolic impact of COVID-19 in people with diabetes and to improve post-COVID diabetes management.
調査の概要
詳細な説明
The DMD-COV study is a prospective, non-interventional, multicenter cohort study conducted in Algeria. The study aims to describe the cardio-metabolic outcomes of adult patients with diabetes following hospitalization for COVID-19.
Patients with type 1 or type 2 diabetes who were hospitalized for laboratory-confirmed COVID-19 (PCR, serology, or antigen test) will be included during hospitalization or within 30 days after discharge. The study does not interfere with routine clinical care, and all therapeutic decisions are made according to usual medical practice.
Approximately 200 patients will be enrolled across multiple university hospital centers. Participants will be followed for one year, with four scheduled visits: at baseline (inclusion), 3 months, 6 months, and 12 months after hospital discharge.
Data collected during the study include demographic characteristics, diabetes history, comorbidities, COVID-19 severity markers, duration of hospitalization, and treatments received during the acute phase, including corticosteroids and anticoagulants. At each follow-up visit, clinical parameters (weight, body mass index, waist circumference), glycemic control (HbA1c, fasting plasma glucose), lipid profile, renal function, and diabetes treatments will be recorded.
The primary outcome is glycemic control, assessed by the proportion of patients achieving their individualized HbA1c target at 6 months and 12 months after hospitalization. Secondary outcomes include changes in HbA1c over time, evolution of diabetes treatments, weight changes, lipid profile, renal function, and identification of factors associated with good glycemic control after COVID-19.
This study will provide valuable real-world data on the metabolic evolution of patients with diabetes after COVID-19 and may contribute to optimizing long-term follow-up strategies in this population.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
El Biar
-
Algiers、El Biar、アルジェリア
- Djillali Belkhenchir Public Hospital (formerly Birtraria)
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Age 18 years or older
- Diagnosis of type 1 or type 2 diabetes mellitus
- Hospitalization for laboratory-confirmed COVID-19
- Inclusion during hospitalization or within 30 days after hospital discharge
- Signed informed consent
Exclusion Criteria:
- Age under 18 years
- Absence of diabetes mellitus
- Refusal or inability to provide informed consent
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Diabetic patients hospitalized for COVID-19
Adult patients with type 1 or type 2 diabetes who were hospitalized for confirmed COVID-19 and followed prospectively after hospital discharge to assess cardio-metabolic outcomes over a one-year period.
|
This is a non-interventional observational study.
No experimental or therapeutic intervention is assigned as part of the study protocol.
All medical care and treatments are provided according to routine clinical practice.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Glycemic control after hospitalization for COVID-19
時間枠：6 months and 12 months after hospital discharge
|
Proportion of patients achieving their individualized HbA1c target according to international diabetes guidelines.
|
6 months and 12 months after hospital discharge
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in HbA1c over follow-up
時間枠：Baseline, 3 months, 6 months, and 12 months
|
Mean change in HbA1c from baseline to 3 months, 6 months, and 12 months after hospital discharge.
|
Baseline, 3 months, 6 months, and 12 months
|
|
Change in body weight and body mass index
時間枠：Baseline, 3 months, 6 months, and 12 months
|
Change in body weight and body mass index (BMI) during follow-up.
|
Baseline, 3 months, 6 months, and 12 months
|
|
Evolution of diabetes treatment
時間枠：Up to 12 months after hospital discharge
|
Changes in diabetes treatment regimen during follow-up, including insulin initiation or intensification and modification of oral or injectable antidiabetic therapies.
|
Up to 12 months after hospital discharge
|
|
Changes in lipid profile and renal function
時間枠：Baseline, 6 months, and 12 months
|
Changes in lipid profile parameters and renal function during follow-up after COVID-19 hospitalization.
|
Baseline, 6 months, and 12 months
|
|
Factors associated with poor glycemic control after COVID-19
時間枠：Up to 12 months after hospital discharge
|
Identification of clinical and therapeutic factors associated with failure to achieve individualized HbA1c targets after hospitalization for COVID-19.
|
Up to 12 months after hospital discharge
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- DMD-COV
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。